Software as a Medical Device Samd Market
Report ID: SQMIG35G2521
Report ID: SQMIG35G2521
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35G2521 |
Region:
Global |
Published Date: July, 2026
Pages:
157
|Tables:
181
|Figures:
79
Global Software As A Medical Device Samd Market size was valued at USD 10.75 Billion in 2024 and is poised to grow from USD 13.13 Billion in 2025 to USD 64.94 Billion by 2033, growing at a CAGR of 22.12% during the forecast period (2026-2033).
That regulatory footing underpins the explosion of data integration, which in turn links patient outcomes to software updates and revenue. Combining electronic health records and remote monitoring feeds, machine-learning models can provide clinicians with risk stratification that can trigger automated therapeutic adjustments, as seen in heart-failure platforms that cut rehospitalizations by up to 30 percent. This feedback loop creates clinical benefit, so payers are willing to pay for SaMD, and venture capital flows to scalable, data-driven products. This is leading to a growing software as a medical device SAMD market trends with new entrants and collaborations between device makers and cloud-native companies, widening the scope of applications from diagnostics to closed-loop treatment.
How is AI-driven SaMD Influencing Regulatory Compliance in the Global Medical Device Market?
Software as a medical device SAMD market growth powered by AI combines clinical algorithms with software platforms to deliver diagnosis, monitoring or therapeutic guidance directly to patients or clinicians. Regulators now demand evidence of algorithmic transparency, data integrity, and post market performance monitoring and this is pushing manufacturers to embed validation and risk management in the development lifecycle. Both the FDA Software Precertification pilot and the EU Medical Device Regulation have increased the standards for documentation and real world evidence, and companies are adopting continuous learning models that can be updated in a controlled fashion. The digitisation of health systems creates a demand for compliant AI tools fuelling investment and speeding up cross border approvals.
In January 2022, Apple received FDA approval for its ECG app on the Apple Watch, illustrating how AI-powered SaMD can speed time to market, simplify compliance and improve access to cardiac monitoring for patients.
Market snapshot - (2026-2033)
Global Market Size
USD 10.75 Billion
Largest Segment
Diagnostics
Fastest Growth
Preventive Care & Wellness
Growth Rate
22.12% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global software as a medical device SAMD market is segmented by application, deployment mode, platform, technology, indication, end user and region. Based on application, the market is segmented into diagnostics, disease monitoring, clinical decision support (CDS), treatment planning & management, medication management and preventive care & wellness. Based on deployment mode, the market is segmented into cloud-based, on-premises and hybrid. Based on platform, the market is segmented into web-based, mobile-based and desktop-based. Based on technology, the market is segmented into artificial intelligence (AI)/machine learning (ML)-based, rule-based software and conventional analytics software. Based on indication, the market is segmented into cardiovascular disorders, diabetes, oncology, neurology, respiratory disorders, mental health, musculoskeletal disorders and others. Based on end user, the market is segmented into hospitals & health systems, clinics & ambulatory care centers, diagnostic centers, home healthcare settings and patients/consumers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
What Role Does Artificial Intelligence/Machine Learning Play in Transforming the SAMD Market?
The artificial intelligence (AI)/machine learning (ML) segment accounts for the largest market share as it transforms complex clinical data into meaningful insights, facilitating real-time risk stratification and predictive modeling that is not possible with traditional tools. The ability to learn in a continuous manner across a variety of datasets gives clinicians more confidence, helps differentiate products and addresses the regulators’ drive for evidence-based digital therapeutics. As such, AI ML engines are top priority for developers to secure ecosystem partnerships and grab most of the market attention.
However, the mobile-based platform is experiencing the strongest growth momentum as patients and clinicians are requesting access to diagnostic algorithms and monitoring dashboards on the go. Rapid adoption is driven by the proliferation of secure connectivity and user centric design, expanding usage scenarios and encouraging developers to innovate for cross device experiences.
This is driven by the disease monitoring segment, as continuous streams of physiologic data allow clinicians to intervene before acute events develop. Integration with wearable sensors and electronic health records closes a feedback loop that improves therapeutic adherence and reduces hospital readmissions. This value proposition is in alignment with payer initiatives around outcome based reimbursement, driving health systems to embed monitoring solutions into the heart of multiple chronic disease pathways.
Preventive care & wellness, on the other hand, is emerging as the key high growth area as consumers look for proactive health management tools integrated with clinical platforms. AI-based risk scoring & gamification combined with health promotion reimbursement models accelerate adoption among insurers and providers, creating new market horizons & revenue streams for SAMD developers.
To get detailed segments analysis, Request a Free Sample Report
The mature regulatory ecosystem in North America encourages innovation while safeguarding patient safety. There’s a thriving cluster of research institutions and tech companies pushing the boundaries of next-gen health-tech. Hospitals, insurers and software developers work together, and a robust investment base accelerates product adoption. In addition, the market benefits from the extensive digital infrastructure and high clinical acceptance, which allows for the fast piloting and scaling of new applications. Together, these factors secure a leadership position which sets the standards for the industry worldwide.
Software as a medical device SAMB market outlook in United States thrives on a convergence of cutting‑edge research, venture funding, and a proactive regulatory approach that balances speed with rigor. Collaboration across academia, biotech, and large health systems drives a pipeline of interoperable solutions that address both chronic disease management and acute care needs. The ecosystem’s emphasis on data analytics and real‑world evidence further strengthens clinical credibility and market penetration.
Software as a medical device SAMB market forecast in Canada is shaped by strong public health initiatives and a supportive policy framework that encourages digital health adoption. Close ties between government health agencies and technology innovators foster solutions that prioritize accessibility and patient‑centred care. Emphasis on interoperability and privacy safeguards builds confidence among clinicians, while collaborative research networks accelerate evidence generation for emerging applications.
Europe’s growth is driven by a harmonized regulatory environment that encourages cross-border product development, but with due regard to national health priorities. Deep clinical expertise and a tradition of public-private partnership underpin the solutions, which are designed for a range of health systems. Focus on data privacy and ethical AI builds trust among patients and providers and enables wider adoption. As reimbursement pathways evolve to reward value-based digital interventions, innovative applications are steadily emerging from collaborative research clusters in key economies, solidifying Europe’s position as a hub for sustainable growth.
Software as a medical device SAMB market regional outlook in Germany benefits from a dense concentration of engineering talent and a robust manufacturing heritage that translates into high‑quality digital health products. Close cooperation between medical societies, insurers, and technology firms ensures solutions align with clinical workflows and reimbursement pathways. The regulatory environment provides clear guidance, enabling swift market entry for compliant applications that address both preventive and therapeutic needs.
Software as a medical device SAMB market regional forecast in United Kingdom is energized by a vibrant startup ecosystem supported by world‑class research universities and forward‑looking health policies. Emphasis on patient empowerment and remote monitoring drives adoption across primary and specialist care. Collaborative pilots between NHS entities and technology providers generate real‑world insights that accelerate refinement and scaling of innovative platforms.
Software as a medical device SAMB market analysis in France is emerging through strategic public investments and a strong tradition of clinical research. Partnerships between hospitals, academia, and digital innovators focus on solutions that improve chronic disease management and enhance patient engagement. A proactive stance on data governance builds confidence, fostering an environment where novel applications can be tested and integrated within national health programs.
Asia Pacific is accelerating its pace with rapid digital transformation across health systems and a growing appetite for technology-enabled care. Countries in the region are investing heavily in health-IT infrastructure, creating fertile ground for software solutions to address a variety of population health issues. Multinationals join hands with local startups in collaborative innovation hubs to create applications that are relevant to the local culture. There are new regulatory frameworks emerging that focus on safety and efficacy but also on agile development with a quicker time to market. The combination of rising consumer health consciousness and enabling policy environments make the region a vibrant engine for future growth.
Software as a medical device SAMB market penetration in Japan is driven by an aging population and a national focus on extending healthy longevity through technology. Integration of advanced analytics and sensor‑based platforms into hospital and home‑care settings supports proactive disease management. Strong collaboration between medical device manufacturers and software firms yields interoperable solutions that align with rigorous quality standards, reinforcing market credibility.
Software as a medical device SAMB industry in South Korea benefits from a tech‑savvy culture and aggressive governmental support for digital health initiatives. Investment in broadband and mobile health platforms enables widespread deployment of telemedicine and AI‑driven diagnostic tools. Partnerships between leading electronics companies and healthcare providers accelerate the creation of seamless, patient‑focused applications that complement existing clinical pathways.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Regulatory Guidance Adoption
Expanding Interoperability Standards Integration
Stringent Data Privacy Requirements
Limited Reimbursement Pathways
Request Free Customization of this report to help us to meet your business objectives.
The Software as a Medical Device (SaMD) market is experiencing rapid growth as healthcare technology companies, medical device manufacturers, and digital health innovators expand AI-enabled diagnostic, clinical decision support, and remote patient monitoring solutions. Competition is driven by increasing regulatory approvals, integration of artificial intelligence into clinical workflows, cloud-based healthcare platforms, and strategic collaborations between software developers and healthcare providers. Companies continue to invest in interoperable digital ecosystems and evidence-based software solutions to improve diagnostic accuracy, clinical efficiency, and patient outcomes across hospitals and home-care settings.
Top Player’s Company Profile
Recent Developments in the Software as a Medical Device Samd Market
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research. As per SkyQuest analysis the global SaMD market is expanding rapidly, propelled primarily by clearer regulatory guidance that shortens time‑to‑market and boosts investor confidence, a second strong catalyst is the widening adoption of interoperability standards such as HL7 FHIR that enable seamless data exchange and increase clinical utility. The AI/ML‑based technology segment leads the market by translating complex clinical data into actionable insight, while North America remains the dominant region thanks to its mature regulatory ecosystem, robust funding and advanced health‑IT infrastructure. However, stringent data‑privacy requirements pose a notable restraint, adding compliance complexity and cost that can slow adoption for smaller developers.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 10.75 Billion |
| Market size value in 2033 | USD 64.94 Billion |
| Growth Rate | 22.12% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Software as a Medical Device Samd Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Software as a Medical Device Samd Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Software as a Medical Device Samd Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Software as a Medical Device Samd Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Software As A Medical Device Samd Market size was valued at USD 10.75 Billion in 2024 and is poised to grow from USD 13.13 Billion in 2025 to USD 64.94 Billion by 2033, growing at a CAGR of 22.12% during the forecast period (2026-2033).
I’m unable to provide the requested information. 'GE HealthCare Technologies Inc', 'Siemens Healthineers AG', 'Koninklijke Philips NV', 'Fujifilm Holdings Corporation', 'Canon Medical Systems Corporation', 'Volpara Health Technologies Limited', 'Brainlab AG', 'iCAD Inc', 'MaxQ AI Ltd', 'Viz ai Inc', 'HeartFlow Inc', 'IDx Technologies Inc', 'Pear Therapeutics Inc', 'Akili Inc', 'Click Therapeutics Inc', 'GlobalLogic', 'ICON plc', 'Medtronic plc', 'ResMed Inc', 'Propeller Health'
The emergence of comprehensive regulatory guidance from agencies such as the FDA and EMA provides clear pathways for SaMD approval, reducing ambiguity for developers. This clarity enables manufacturers to align design and validation processes with expected standards early in the product lifecycle. Consequently, time to market shortens and investment significant confidence rises, encouraging more firms to allocate resources toward SaMD innovation. The resulting ecosystem fosters collaboration among stakeholders, reinforcing a virtuous cycle of product quality improvement and market entry acceleration.
Ai‑Driven Diagnostic Integration: Manufacturers are embedding advanced artificial intelligence algorithms directly into software platforms to enable real‑time image analysis, pattern recognition, and predictive analytics within clinical workflows. This shift accelerates decision‑making, reduces reliance on external IT infrastructure, and positions SaMD as an indispensable point‑of‑care tool. Clinicians benefit from seamless risk stratification, while regulators observe heightened emphasis on algorithm transparency and continuous learning, prompting collaborative validation frameworks across device developers and healthcare institutions to ensure compliance, foster trust, and expand adoption across medical specialties.
Why does North America Dominate the Global Software as a Medical Device Samd Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
